5-溴-6-甲基吡嗪-2-羧酸甲酯 | 1823888-27-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-溴-6-甲基吡嗪-2-羧酸甲酯
• 英文名称: methyl 5-bromo-6-methylpyrazine-2-carboxylate
• CAS: 1823888-27-2
• 化学式: C₇H₇BrN₂O₂
• 分子量: 231.049
• InChiKey: JQSCMRUAOPYORA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5-溴-6-甲基吡嗪-2-羧酸甲酯 在 硫酸 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 N-(2-(5-bromo-6-methylpyrazin-2-yl)propan-2-yl)-2-chloroacetamide
  参考文献：
  名称：

  [EN] ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF
  [FR] ANTAGONISTES DU RÉCEPTEUR DE L'ADÉNOSINE, COMPOSITIONS PHARMACEUTIQUES ET LEUR UTILISATION

  摘要：

  In its many embodiments, the invention provides compounds of structural Formula (I): (I), and pharmaceutically acceptable salts thereof, wherein, ring A, R1, R2and R3are as defined herein, and pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents). The invention further provides methods for the preparation and use of the compounds of the invention, or a pharmaceutically acceptable salt thereof, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

  公开号：

  WO2023158626A1
• 作为产物：
  描述：

  5-氯-6-甲基吡嗪-2-甲酸甲酯 在 三甲基溴硅烷 作用下， 以 乙腈 为溶剂， 生成 5-溴-6-甲基吡嗪-2-羧酸甲酯
  参考文献：
  名称：

  [EN] ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF
  [FR] ANTAGONISTES DU RÉCEPTEUR DE L'ADÉNOSINE, COMPOSITIONS PHARMACEUTIQUES ET LEUR UTILISATION

  摘要：

  In its many embodiments, the invention provides compounds of structural Formula (I): (I), and pharmaceutically acceptable salts thereof, wherein, ring A, R1, R2and R3are as defined herein, and pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents). The invention further provides methods for the preparation and use of the compounds of the invention, or a pharmaceutically acceptable salt thereof, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

  公开号：

  WO2023158626A1

文献信息

• Pyrazinecarboxamide derivatives as CB1 antagonists
  申请人：Hebeisen Paul

  公开号：US20070293509A1

  公开（公告）日：2007-12-20

  The present invention relates to compounds of the formula I: wherein R 1 to R 8 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity.

  本发明涉及以下式I的化合物： 其中R1至R8如描述和索赔中定义，并且其药学上可接受的盐。这些化合物对于治疗和/或预防与调节CB1受体相关的疾病，如肥胖症，是有用的。
• PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS CB2 RECEPTOR MODULATORS
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP2076499B1

  公开（公告）日：2010-05-12
• US7629346B2
  申请人：——

  公开号：US7629346B2

  公开（公告）日：2009-12-08